Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...
Le Lézard5m
Implantica's RefluxStoptm garners strong interest at SAGES
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...